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Abstract
Background: Radiation therapy is an indispensable part of various treatment modalities for breast cancer.
Specifically, for non-inflammatory locally advanced breast cancer (LABC) patients, preoperative radiotherapy
(pRT) is currently indicated as a second line therapy in the event of lack of response to neoadjuvant
chemotherapy. Still approximately one third of patients fails to respond favourably to pRT. The aim of this
study was to explore molecular mechanisms underlying differential response to radiotherapy (RT) to identify
predictive biomarkers and potential targets for increasing radiosensitivity.
Methods: The study was based on a cohort of 134 LABC patients, treated at the Institute of Oncology and
Radiology of Serbia (IORS) with pRT, without previous or concomitant systemic therapy. Baseline transcriptional profiles
were established using Agilent 60 K microarray platform in a subset of 23 formalin-fixed paraffin-embedded (FFPE)
LABC tumour samples of which 11 radiotherapy naïve and 3 post-radiotherapy samples passed quality control
and were used for downstream analysis. Biological networks and signalling pathways underlying differential
response to RT were identified using Ingenuity Pathways Analysis software. Predictive value of candidate genes in the
preoperative setting was further validated by qRT-PCR in an independent subset of 60 LABC samples of which 42 had
sufficient quality for data analysis, and in postoperative setting using microarray data from 344 node-negative breast
cancer patients (Erasmus cohort, GSE2034 and GSE5327) treated either with surgery only (20%) or surgery with RT (80%).
Results: We identified 192 significantly differentially expressed genes (FDR < 0.10) between pRT-responsive and
non-responsive tumours, related to regulation of cellular development, growth and proliferation, cell cycle
control of chromosomal replication, glucose metabolism and NAD biosynthesis II route. APOA1, MAP3K4, and MMP14
genes were differentially expressed (FDR < 0.20) between pRT responders and non-responders in preoperative setting,
while MAP3K4 was further validated as RT-specific predictive biomarker of distant metastasis free survival (HR = 2.54,
[95%CI:1.42–4.55], p = 0.002) in the postoperative setting.
Conclusions: This study pinpoints MAP3K4 as a putative biomarker of response to RT in both preoperative and
postoperative settings and a potential target for radiosensitising combination therapy, warranting further pre-
clinical studies and prospective clinical validation.
Keywords: Preoperative radiotherapy, Locally advanced breast cancer, Biomarker, Gene expression profiling
* Correspondence: m.tanic@ucl.ac.uk
1Laboratory for Molecular Genetics, Institute of Oncology and Radiology of
Serbia, Belgrade, Serbia
3Medical Genomics, UCL Cancer Institute, University College London,
London, UK
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Tanić et al. Radiation Oncology  (2018) 13:193 
https://doi.org/10.1186/s13014-018-1129-4
Background
Non-inflammatory locally advanced breast carcinoma
(LABC) is a late stage breast cancer presented as a bulky
primary chest wall tumour and/or extensive adenopathy
including patients with large (> 5 cm), usually inoperable
tumours and node positive disease [1]. It is a common
presentation worldwide but is of special concern in de-
veloping countries with limited breast cancer awareness
and efficient population screening programs. For in-
stance, in Serbia over 4500 new breast cancer cases are
diagnosed each year, with as many as 30% presenting as
late stage initially inoperable LABC.
A multimodal approach including systemic therapy,
radiotherapy and surgery is usually applied in the treat-
ment of LABC [2]. Currently, neoadjuvant systemic ther-
apy (CHT) is usually administered to downstage the
tumour for breast-conserving surgery, while preoperative
radiotherapy (pRT) is often indicated if there is no ob-
jective reduction of tumour volume after the administra-
tion of neoadjuvant (CHT). Radiation therapy (RT) is
frequently used in various modalities for treatment of
breast cancer of different stages including LABC, and
large meta-analyses of multiple randomised trials dem-
onstrated clear long-term benefit both in terms of locor-
egional control and reduced mortality in breast cancer
patients treated with radiotherapy after breast conserv-
ing surgery and after radical mastectomy [3–5]. Given
the rarity of this treatment modality only a few studies
looked into the effects of preoperative radiotherapy
(pRT) in combination with breast conserving surgery on
locoregional recurrence and overall survival reporting
similar results compared to protocols involving neoadju-
vant chemotherapy without irradiation [6–9]. However,
the molecular basis of tumour sensitivity to radiotherapy
is complex, and at present, there are no conclusive bio-
markers in clinical use to predict if a patient will, in fact,
benefit from radiotherapy.
The concept of personalised medicine has been success-
fully implemented in medical oncology for over a decade
with several biomarkers approved for clinical use. The
same principle could be applied to radiation oncology to
achieve better clinical responses to radiotherapy, lower
radio-toxicity and avoid overtreatment [10, 11]. To
achieve this goal there is a clear need to develop bio-
markes specific for breast radiotherapy. Hovewer, most of
the studies in radiation oncology have been limited to the
study of biomarkers not necessarily chosen based on their
specificity to radiotherapy. Molecular subtypes have
shown limited predictive estimation of RT efficacy and
have been potentially confounded by adjuvant systemic
therapy [11–13]. Several studies aimed to identify a radio-
sensitivity molecular signature in breast cancer by study-
ing changes in gene and protein expression in response to
radiation in cellular and animal model systems. These
included determination of cellular radiosensitivity defined
by survival fraction at 2 Gy [14], clonogenic doubling
time, hypoxic fraction, or clonogenic number [15], with
some of these multigene signatures having been validated
in retrospective studies in solid tumours including breast
cancer [16–18].
Although these studies provided valuable insights into
cellular radiation response, the breast tissue has a com-
plex microenvironment composed of several interacting
cell types and extracellular molecules that may affect
tumour response. The ideal model system for research-
ing the breast tumour response to radiation therapy and
evaluating the predictive value of markers is the pre-
operative setting [19, 20]. Detection and characterization
of biomarkers in the patient’s tumour biopsies with
known clinical response, before and after radiation ther-
apy could select the group of patients with worse re-
sponse to radiotherapy, to facilitate the choice of more
efficient treatment, avoid overtreatment and consequen-
tially reduce associated healthcare costs.
Leveraging a cohort of LABC patients treated with pRT
without neoadjuvant or concomitant CHT (IORS LABC
cohort) we determined baseline molecular differences be-
tween radio-resistant and radio-responsive breast tumours
and identified putative predictive biomarkers of response
to pRT. In our previous study on this cohort [21] we have
shown that the extent of the clinical response to pRT in
LABC is predictive of overall survival. Here, we analysed
global gene expression patterns and biological pathways
associated with differential response to pRT in a discovery
subset of the IORS LABC cohort. Selected biomarkers
were validated by an orthogonal assay (qPCR) in an inde-
pendent validation set of pRT IORS LABC samples, and
in the postoperative setting using an external microarray
dataset (Erasmus cohort) consisting of breast cancer pa-
tients treated only with radiotherapy following surgery.
Methods
Patient cohorts
IORS LABC cohort
This retrospective cohort included 134 patients with lo-
cally invasive non-inflammatory breast cancer (LABC) (93
patients stage III-a, and 41 patients III-b) treated with
pRT between 1997 and 2000, delivering 45Gy in 15 frac-
tions every second day alternately to the breast and re-
gional lymph nodes, followed by radical mastectomy and
adjuvant chemo and/or hormonal therapy (Fig. 1a). The
median follow-up was 74 months (4–216) counted from
the breast cancer diagnosis until last check-up or death
from any cause. Five-year overall survival was 56% and
5-year disease free survival was 39.2%. Tumour biopsy
was taken both prior to radiation treatment to obtain a
radiotherapy-naïve sample (series A), and after RT and
radical mastectomy before adjuvant treatment (series B)
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stored as formalin-fixed paraffin-embedded (FFPE) tissue
samples. Clinical response to pRT in the breast was defined
per RECIST criteria [22]. All patients gave their informed
written consent for the use of residual tissue for research.
The study was approved by the Institute of Oncology and
Radiology Ethical Review Board for human studies. An
overview of the patients’ clinicopathological characteristics
is summarised in Additional file 1: Table S1.
Erasmus breast cancer cohort
For biomarker validation, we have used a previously
published clinical data set from the Erasmus cohort
(GSE2034 and GSE5327). This cohort includes 344
lymph-node negative breast cancer patients treated at
the Erasmus Medical Center (Rotterdam, Netherlands)
from 1980 to 1995, who had not received neoadjuvant nor
adjuvant systemic treatment [23]. Primary treatment was
breast-conserving surgery or modified radical mastec-
tomy, and 87% of the patients received postoperative RT.
Early metastasis was defined as distant recurrence in the
first 5 years following completion of primary treatment.
RNA extraction from FFPE tissue
Tumour tissue sections were stained with H&E and ex-
amined by a pathologist. Tumour tissue was macrodi-
sected prior to RNA extraction to ensure there was >
70% tumour content. Total RNA was extracted from 3
to 5 10 μm thick FFPE tissue sections using RNeasy
A
B
Fig. 1 a Infographic summarizing treatment protocol and sample collection of locally advanced breast cancer patients treated at the Institute of
Oncology and Radiology of Serbia between 1997 and 2000 (IORS-LABC cohort). The IORS-LABC cohort included 134 patients who had initial
biopsy taken before any treatment, followed by radiotherapy and radical mastectomy. Exceeding tumour material was formalin-fixed and paraffin
embedded (FFPE) and stored at room temperature. b Flowchart representing the study outline for sample processing, quality control, data analysis
and biomarker validation. FFPE samples were review by a pathologist to select those with > 70% of tumour material, retaining 118 pre-RT biopsy
tumour samples (a) and 21 post-RT tumour samples (b). These samples were split into discovery (NA = 22 pre-RT and NB = 21 post-RT) and validation
(NA = 96) subsets. After quality control of extracted RNA only 23 samples from the discovery subset were selected for microarray hybridization (NA = 18
and NB = 5), of which only 14 (NA = 11 and NB = 3) passed data quality control. Out of 96 pre-RT samples designated for validation, only 60 had passed
RNA quality control and were used for qRT-PCR. Of those, 42 samples passed data quality control and were retained for the downstream analysis
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FFPE Kit (Qiagen) with an 18-h Proteinase K tissue di-
gestion step. RNA quantity and purity were assessed by
BioSpec-nano (Shimadzu Scientific Instruments).
Microarray hybridization and data analysis
Agilent SurePrint G3-Hmn-GE-v.2-8x60K Microarray
platform was used for gene expression profiling follow-
ing Agilent Gene Expression FFPE Workflow. Raw data
pre-processing and quality control was performed using
R version 3.0.1 and R/Bioconductor packages ‘limma’,
‘ffpe’ and ‘ArrayQualityMetrics’. Data were deposited in
the GEO database under the GSE101920 accession num-
ber. Hierarchical average linkage clustering was per-
formed using Cluster 3.0 and visualised using
JavaTreeView [24]. Differential expression analysis was
performed using the POMELO II tool applying moder-
ated t-test [25]. The estimated significance levels were
corrected for multiple hypotheses testing using Benja-
mini and Hochberg False Discovery Rate (FDR) adjust-
ment [26]. The ranked target list of the differentially
expressed genes was subjected to pathway enrichment
analyses using Ingenuity Pathway Analysis software (In-
genuity Systems). Significantly enriched gene networks
and canonical pathways based on the curated IPA data-
base KEGG, Biocarta, and Reactome, were identified as
previously described [15]. Methods are described in de-
tail in Additional file 2: Supplementary Methods.
Quantitative RT-PCR and statistical analysis
Applied Biosystems High Capacity cDNA Reverse Tran-
scription Kit was used for preparing cDNA from 200 ng
RNA. Quantitative RT-PCR was done on an ABI Prism
7300 (Applied Biosystems) using TaqMan® Gene Expres-
sion Assays and TaqMan® PreAmp Master Mix Kit (Life
Technologies). All qPCR amplicons were designed to be
less than 100 bp long and all assays were done in tripli-
cate. Assay ID numbers are shown in Supplementary
Table 4. Each plate included a HeLa cell line as
inter-plate calibrator (IPC) and a non-template control
(NTC). Average Ct values for each gene were standar-
dised to IPC, dCt values were calculated relative to
ACTB as a reference gene. Genes and samples with over
70% of missing values were excluded from further ana-
lysis, retaining 8 genes and 42 samples for further ana-
lysis. Undetermined values were set to the number of
cycles performed (Ct = 45). Data was log2 transformed
and differences in gene expression levels between groups
were tested using Student t-test and corrected for mul-
tiple testing with FDR set to 20%.
Erasmus dataset processing and statistical analysis
Erasmus dataset was downloaded from GEO database and
processed using affy R package. Distant metastasis free
survival (DMFS) was defined as any distant recurrence
within 5 years after the end of treatment. Survival curves
were plotted with the Kaplan–Meier method and log-rank
test was used to evaluate differences between groups de-
fined by candidate gene expression status. Cutoff Finder
was used to determine the optimal cutpoint for gene ex-
pression dichotomization based on the log-rank test mini-
mum P-value approach [27]. Hazard ratios were estimated
using the Cox proportional hazards model, stratified by
RT status in a univariable and multivariable analysis. Pear-
son’s χ2 test was used to check for unbalanced distribution
of clinico-pathologcal varables (ER, PR, T-stage and age
categories) in subgroup analysis (Additional file 3: Table
S2). Measures of biological interaction were determined
both on additive scale and multiplicative scale [28, 29].
Stata command icp was used for calculating 3 different
measures of interaction contrast on an additive scale: rela-
tive excess risk due to interaction [RERI], attributable pro-
portion [AP] and synergy index [S] as described in [30].
Multiplicative interaction was assessed by including an
interaction term with main effects in the Cox proportional
hazard model. Statistical calculations were performed
using STATA version 11.2 (StataCorp). All reported
p-values were two-sided with a 0.05 significance level.
Results
Molecular signature of radiosensitivity in LABC tumour
samples
To gain a better understanding of the molecular response
to radiotherapy independently of systemic treatment and to
identify a baseline transcriptional signature of radiosensitiv-
ity between radio-responsive and non-responsive tumours,
we have analysed radiotherapy-naïve LABC tumour biop-
sies and post radiotherapy mastectomy samples by gene ex-
pression profiling. A total of 43 FFPE tumour samples (NA
= 22, NB = 21) from the patient cohort was randomly se-
lected maintaining balanced group representation of clinical
response (CR, PR, SD) and other clinicopathological char-
acteristics (Additional file 4: Table S1). Of those, due to the
low concentration or purity of the RNA extracted from
FFPE only 23 samples were selected for microarray
hybridization. Following stringent microarray quality con-
trol 14 samples (NA = 11, NB = 3) were included in subse-
quent data analysis (Additional file 4: Figure S1),
comprising of 8 patients with stable disease designated as
non-responders (NR) and 6 patients which experienced ei-
ther complete (2 pts) or partial clinical response (4 pts) to
pRT, classified as responders (R) (Fig. 1b).
Although unsupervised clustering analysis over top
20% most variable transcripts revealed separation be-
tween non-responders and responders (Additional file 5:
Figure S2), not enough post-RT samples were left after
QC to draw relevant conclusions regarding changes in
pRT response between pre-RT and post-RT biopsies.
Therefore, to study intrinsic differences underlying
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differential response to radiotherapy in the neoadjuvant set-
ting, we have analysed only pre-RT tumour samples (NA =
11) to look for differences in baseline transcriptional pro-
files between responders (R) and non-responders-(NR). We
identified 192 significantly differentially expressed mRNA
transcripts (> 2-fold change and FDR < 0.1), including 89
annotated protein coding genes (PCG) and 78 long
non-coding RNAs (lncRNAs) (Additional file 6: Table S3).
Of those, only 7 genes were found to be upregulated while
the rest of the genes (185) were downregulated in
radio-responsive tumours (R) (Fig. 2a). The top 20 differen-
tially expressed PCG are listed in Table 1.
To elucidate which biological processes and signalling
pathways are associated with differential response to
pRT, we have applied a gene set enrichment analysis
using Ingenuity Pathways Analysis software. The bulk of
differentially expressed genes were organised in two top
scoring gene networks: lipid metabolism, molecular
transport and small molecule biochemistry (Network 1)
and cell cycle, DNA replication, recombination, and re-
pair (Network 2) (Additional file 7: Figure S3). Specific-
ally, differentially activated canonical pathways (Fisher’s
test p < 0.05) between pRT responders and non-
responders, included cell cycle control of chromosomal
replication, and pathways related to glucose metabolism
and de novo NAD biosynthesis (Fig. 2b). Similarly, mo-
lecular functions significantly enriched within the list of
differentially expressed genes included cellular develop-
ment, cell growth and proliferation, cell cycle and func-
tions related to cell morphology, movement, assembly and
organisation in addition to metabolic processes (Fig. 2c).
Candidate gene validation by qRT PCR
Even after controlling for false discovery rate, due to the
small size of the discovery cohort and technical chal-
lenges related to FFPE-based microarray hybridization,
several associations with the outcome of interest may
have occurred due to chance alone. Therefore, we
A B
C
Fig. 2 a Supervised average linkage hierarchical clustering of 11 preRT FFPE tumour samples from locally advanced breast cancer (LABC) patients
treated with preoperative radiotherapy (pRT) over 192 significantly differentially expressed gene transcripts. b Significantly enriched Canonical
pathways and (c) Molecular functions identified by Ingenuity Pathway Core Analysis
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proceeded to validate a selected panel of genes in an
independent set of pre-RT tumour samples (NA = 60)
using an orthogonal assay (qRT-PCR). Ten genes
(CHEK2, XRCC2, MCM6, MAP3K4, MMP14, APOA1,
WHSC1L1, IDO1, ST3GAL-4 and A1CF) were selected
for validation based on the significance threshold,
high expression in tumour tissue and plausible bio-
logical function. Samples in which over 70% of assays
have failed were discarded, retaining 42/60 samples
for statistical analysis (Fig. 1b). Considering the cost
of missing a potentially interesting gene (false nega-
tive) versus the low cost of further external validation
to discard any false positive calls, we decided to use a
lax False Discovery Rate of 20%. Differential gene ex-
pression between responders (NR = 30) and non-re-
sponders (NNR = 12) was observed for APOA1,
MAP3K4 and MMP14 genes with over 2-fold down-
regulation in pRT-responsive tumours (Table 2).
External validation of candidate gene predictive value for
radiotherapy response
To evaluate whether expression of APOA1, MAP3K4
and MMP14 genes has an impact on patient survival
in the postoperative setting, we analysed distant
metastasis-free survival (DMFS) using a
well-characterized cohort of 344 lymph node-negative
breast patients undergoing surgical treatment, with or
without postoperative radiotherapy (Erasmus cohort)
(Fig. 1b). The Erasmus cohort was chosen to elimin-
ate potential confounding effects of systemic therapy,
and to asses weather these genes are radiation-specific
(predictive) or not (simply prognostic) in a stratified
analysis. Of the three genes tested in a subgroup
analysis, only low MAP3K4 expression (< 7.94) was
significantly associated with better DMFS (HR= 2.41
[95%CI:1.37–4.24], p= 0.002) in 282 patients treated with
both surgery and RT, but not for those 62 patients
Table 1 Top 20 significantly differentially expressed protein coding genes between pRT responsive and non-responsive tumor
samples
# Gene Symbol Gene Name FDR-adjusted q-value Fold Change Super-Pathways
1 ST3GAL4 ST3 beta-galactoside alpha-2,
3-sialyltransferase 4
0.03715## 0.10 protein glycosylation
2 C6orf105
(ADTRP)
chromosome 6 open reading
frame 105 (Androgen-Dependent
TFPI-Regulating Protein)
0.03715## 0.17 No Data Available
3 RAP1GAP2 RAP1 GTPase activating protein 2 0.03781## 0.18 Immune System
4 A1CF APOBEC1 complementation factor 0.03874## 0.17 mRNA Editing and Processing of
Capped Intron-Containing Pre-mRNA
5 MAP3K4 mitogen-activated protein kinase
kinase kinase 4
0.03874## 0.25 MAPK signaling pathway
6 CHD5 chromodomain helicase DNA
binding protein 5
0.05133# 0.15 ATP-dependent helicase activity
7 LAS1L LAS1-like (S. cerevisiae) 0.05209# 0.19 biogenesis of the 60S ribosomal subunit.
8 DEFB128 defensin, beta 128 0.05781# 0.29 Immune System
9 ENHO energy homeostasis associated 0.05781# 0.23 metabolism
10 CECR9 cat eye syndrome chromosome
region, candidate 9 (non-protein coding)
0.05781# 0.20 unknown
11 IDO1 indoleamine 2,3-dioxygenase 1 0.05781# 0.20 Tryptophan metabolism
12 LRRC55 leucine rich repeat containing 55 0.05788# 0.14 ion channel
13 ROGDI rogdi homolog (Drosophila) 0.05788# 0.26 unknown
14 KRT25 keratin 25 0.05796# 0.22 cytoskeleton
15 LAMA4 laminin, alpha 4 0.05798# 0.25 Focal Adhesion, ECM-receptor interaction
16 PLA2G2C phospholipase A2, group IIC 0.05798# 0.15 alpha-Linolenic acid metabolism and
Glycerophospholipid biosynthesis
17 CCDC114 coiled-coil domain containing 114 0.05798# 0.25 cell motility
18 CNGB1 cyclic nucleotide gated channel beta 1 0.05798# 0.27 cAMP binding and intracellular cAMP
activated cation channel activity
19 PRSS53 protease, serine, 53 0.05798# 0.30 serine-type endopeptidase activity
20 GSG1 germ cell associated 1 0.05798# 0.22 RNA polymerase binding
FDR – false discovery rate; Fold change is shown on a linear scale
#q-value < 0.1; ##q-value < 0.05
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undergoing only surgery (HR = 1.93 [95%CI:0.54–6.84],
p = 0.309) indicating that the effect is specific for
RT-treated patients (Fig. 3). After controlling for age,
steroid receptor status, T-stage and menopause status as
potential confounders in a multivariable analysis MAP3K4
remained an independent predictor of DMFS (HR= 2.54,
[95%CI:1.42–4.55], p = 0.002) in RT-treated patients.
(Table 3). To check for the presence of biological inter-
action betweenMAP3K4 levels and radiotherapy, we calcu-
lated hazard ratios for each category combination and
summary measures of effect modification on both multi-
plicative and additive scale. There was no evidence of statis-
tical interaction on a multiplicative scale, while the
combined effect of MAP3K4 levels and radiotherapy on
additive scale exceeded that of each exposure alone with a
0.91 relative excess risk due to interaction [RERI] (Table 4).
Discussion
Treatment of LABC continues to be challenging with pa-
tients being at increased risks of locoregional recurrence,
distant metastasis and reduced quality of life. Breast radio-
therapy was shown to be effective in the locoregional con-
trol and provided benefit in distant metastasis-free survival
and for downstaging the tumour in the preoperative treat-
ment of LABC. However, not all patients achieve a satisfy-
ing response to radiotherapy. Clinically, a tumour is
considered radioresistant when irradiation is unable to re-
duce its volume or when a recurrence occurs after a pos-
sible regression. Thus, it would be beneficial to identify
biomarkers predictive of initial response to pRT that could
be useful to predict clinical outcome in RT treated patients.
Here we explored gene expression profiles in pre- and
post-RT tumour biopsies of LABC samples with
Table 2 Gene expression analysis by qRT-PCR in an independent subset of 42 LABC tumor samples
# Gene
Symbol
Amplicon
Length
Responders (R)(n = 30) Non-responders (NR)(n = 12) p-value Fold
changemean sd mean sd
1 APOA1 63 5.99 1.96 7.55 1.37 0.0161** 0.34
2 CHEK2 109 −4.63 1.69 −4.18 1.06 0.390 0.73
3 IDO1 106 1.06 2.87 0.63 2.82 0.662 1.35
4 MAP3K4 89 −3.00 1.99 −1.78 1.28 0.0582* 0.43
5 MCM6 109 −5.12 1.98 −4.88 2.34 0.741 0.85
6 MMP14 92 7.85 2.85 9.61 2.03 0.0596* 0.30
7 ST3GAL4 60 −3.95 2.68 −3.38 3.32 0.566 0.67
8 WHSC1L1 67 −0.98 3.90 −1.16 4.61 0.979 1.13
9 XRCC2 66 −4.68 2.08 −4.04 2.13 0.455 0.64
Gene expression was determined by qRT-PCR in independent test set of 60 FFPE breast tumors, of wich 42 were retained for data anlysis. Represented data were
interplate calibrated, normalized to B-Actin and log2 transformed. Normality was evaluated using Lilform test. p-values - level of significance according to the
Student’s t-test or nonparametric Kolmogorov-Smirnov test (WHSC1L1 and ST3GAL4), FC fold change gene expression relative to ACTB between pRT responders
(R) to nonresponders (NR) tumors measured by qPR-PCR; Fold change is shown on a linear scale
*p-value < 0.1; **p-value < 0.05
A B
Fig. 3 Association of distant metastasis-free survival with high (red) and low (blue) MAP3K4 expression in Erasmus breast cancer dataset. a Kaplan-
Meier survival estimates of 282 patients treated with surgery and RT (b) Kaplan-Meier survival estimates of 62 patients treated with surgery only
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different clinical response to pRT. However, after micro-
array QC there were too few pre- and post-RT matched
samples to be able to draw any statistically significant
conclusions regarding changes induced by pRT. There-
fore, we focused our further analysis on pre-RT biopsies
only, to establish baseline differences in transcriptional
profiles between patients achieving either complete or
partial clinical response and those who did not respond to
pRT. Among 192 significantly differentially expressed
transcripts, only 89 corresponded to known protein cod-
ing genes and to 78 lncRNA. Although, lncRNAs were
shown to have important roles in a broad range of bio-
logical processes such as at the level of
post-transcriptional processing and transcriptional gene
silencing [6, 7] their biological function in breast cancer,
and especially in relation to radiation therapy remains
unknown.
Using IPA analysis, we explored which gene networks
and signalling pathways are conferring radiation resist-
ance/sensitivity in LABC tumour samples. Looking at
protein interactions, most of the genes were organised
in two major networks, one constituted of genes in-
volved in lipid metabolism, molecular transport and
small molecule biochemistry and the second related to
cell cycle, DNA replication, recombination, and repair.
These results further emphasise the importance of the
cell cycle and proliferation state on cellular radiosensitiv-
ity, in line with the current body of knowledge [31, 32].
Interestingly, when focusing on specific canonical path-
ways in addition to cell cycle control of chromosomal
replication, pathways related to glucose metabolism and
de novo NAD biosynthesis were significantly overrepre-
sented. This profile potentially reflects a comparatively
activated metabolic pathway for de novo synthesis of
NAD+ in radio-resistant tumours. In addition to its nu-
merous functions in redox reactions, NAD+ is a sole sub-
strate for the activity of PARP enzyme in the repair of
DNA single-strand brakes [33, 34]. Several inhibitors of
IDO1 gene, a rate-limiting enzyme for the NAD+ de novo
synthesis from tryptophan found to be downregulated in
radiosensitive LABC tumours, have shown a radiosensitis-
ing effect in in pre-clinical studies, making it an attractive
target for drug-radiation combination therapy [35–37].
The second aim of the study was to identify potential
biomarkers of response to radiotherapy. To this end, we
selected 10 genes to be validated by an orthogonal assay
in an independent subset of LABC tumours. Only 3 genes
(APOA1, MAP3K4 and MMP14) were confirmed to be
downregulated in radiosensitive tumours in the preopera-
tive setting. These markers were further validated in an in-
dependent dataset of breast tumours treated only with
mastectomy with or without postoperative radiotherapy.
Only MAP3K4 gene was found to independently and spe-
cifically predict DMFS in radiotherapy-treated patients.
Patients with high levels of MAP3K4 treated with RT had
shorter DMFS than those with low MAP3K4 levels, due to
an adverse interaction of high MAP3K4 expression with
RT. MAP3K4 is a member of first layer of kinases of the
MAPK signalling pathway that is activated by a variety of
stimuli, including ionizing radiation, to mediate activation
of transcription factors controlling differentiation, prolifer-
ation, cell growth and survival [38]. Increased expression
of MAP3K4 in breast tumours may confer radioresistance
through augmented signalling for RT-induced DNA dam-
age repair through G2 arrest thus aiding survival of irradi-
ated cancer cells [39]. Therefore, detecting the levels of
MAP3K4 expression in breast tumours, may be useful for
the prediction of response to RT for tumour downstaging
for breast conserving surgery in LABC. Furthermore, in-
hibition of Ras-Raf-MEK-ERK cascade was shown to in-
crease radiosensitivity both in in vitro as well as in vivo
studies rendering MAPK signalling as an attractive radio-
sensitising target [40–42].
Table 3 Multivariable Cox regression analysis of distant metastasis free survival in 282 patients treated with radiotherapy and
surgery
Variable Reference vs. level Hazard Ratio (95% CI) p-value
MAP3K4 level (low vs. high) 2.54 (1.42, 4.55) 0.002*
ER/PR status (ER+/PR+ vs. ER-/PR+ or ER+/PR-, ER-/PR-) 1.20 (0.94, 1.52) 0.146
Age (under 40 vs. 40–55, 56–70, over 70) 0.81 (0.53, 1.24) 0.332
Menopause (pre-menopausal vs. postmenopausal) 1.19 (0.58, 2.42) 0.639
T-stage (T1 vs. T2, T3, T4) 1.08 (0.75, 1.55) 0.697
*p-value < 0.01
Table 4 Hazard ratios for distant metastasis free survival with
95% CI in 344 lymph node negative breast cancer patients with
measures of effect modification
MAP3K4 level Radiotherapy Hazard Ratio (95% CI) p-value
low no Reference = 1
low yes 1.33 (0.38, 4.63) 0.652
high no 1.97 (0.56, 6.97) 0.294
high yes 3.21 (1.02, 10.15) 0.047*
Measure of effect modification on additive scale: RERI (95% CI) 0.91 (−0.56,
2.39); P = 0.226
Measure of effect modification on multiplicative scale: ratio of HRs (95% CI)
1.23 (0.31, 4.90); P = 0.773
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The main limitation of this study is a small sample size of
the discovery cohort resulting from suboptimal RNA ex-
tracted from FFPE material, that may have led to inflated
type I error. To mitigate this effect, we performed valid-
ation in larger independent series using an orthogonal
assay. However, the limitation of the qPCR method using
FFPE tissues is that it is sensitive to degraded DNA thus
not all genes could have been detected in all patients’
samples. Despite these limitations, the value of these results
lies in the use of LABC tumour samples exposed only to
RT without systemic therapy administered either previously
or concomitantly with RT, and further validation of candi-
date genes’ effect on DMFS in a large independent cohort
devoid of any confounding effects of systemic therapy.
Conclusions
In summary, this study provides a novel insight into the
underlying biology of intrinsic breast tumour radioresis-
tance and points to genes and pathways that may be tar-
geted to increase radiosensitivity. Additionally, we
identified a putative radiotherapy-specific biomarker of re-
sponse, MAP3K4 that warrants further mechanistic stud-
ies and validation in randomized prospective cohorts to
optimise patient selection and treatment planning.
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